Thanks everyone, I did have a good day!
Now to talk about my rollercoaster life.After being kicked out of the weight loss study because I'm
too short(since they use your height and weight to figure your BMI, I decided I must be too short, not too fat!) I find out that it was not the study that they had originally called me about. I knew that at first they had said the medication was only available in an injectable form, but when they gave me the meds. it was pills. I asked about it, but they said I must have misunderstood, or something. Anyway I*'ve since talked to the co-ordinator of the injectable study and amd set up to be screened for that one on Friday morning.
There is a lot more known about the drung involved in this one. It is a drug that is a manmade hormone of a hormone made in the pancrease, and it has been tested extensively on diabetics. While treating diabetic, the discovered that it seemed to cause weight loss in the people taking it, along with their insulin, well this study is to see if the drug is effective on diabetics who are not on insulin, and also on non-diebetics. What this one is supposed to do is to keep your blood sugar level without all the spikes and valleys. I came back to the office and did a little bit or research on it, and here is some of what I found. The name of the drug is Parmlintide. The hormone it is to represent is AMYLIN. There are two links amd one excerpt from anothe link. I found it very interesting. I hope you do too, and I hope I get to participate in this one.
http://www.defeatdiabetes.org/Articl...loss030916.htm
In the present study, the improvement in glycemic control with pramlintide was associated with significant weight loss. The mechanism underlying the observed weight effect of pramlintide has not yet been systematically studied in humans. However, there is increasing evidence from rodent studies implicating amylin as a centrally acting postprandial satiety signal (29,30). In those studies, amylin dose dependently reduced meal size and overall food intake (29), whereas administration of a selective amylin antagonist increased feeding and body fat stores (30).
Unlike antiobesity agents, which may improve glycemic control as the result of a reduction in body weight (31,32), pramlintide's effects to simultaneously improve glycemic and weight control in patients with type 2 diabetes appear to occur via two independent mechanisms. This is supported by previous studies in which pramlintide selectively reduced postprandial but not fasting glucose concentrations (22,23) and by the finding in the current study that [HbA.sub.1c] was reduced regardless of whether patients gained or lost weight. It is also noteworthy that the observed weight reduction with pramlintide therapy occurred in patients who had been on established insulin therapy and who had been advised to not change their diet and exercise regimen during the study. Further studies are therefore warranted to examine the weight effect of pramlintide when used in conjunction with behavioral modification, as well as during the initiation of insulin therapy, when weight gain is typically most pronounced (4-6).
In conclusion, mealtime amylin replacement with pramlintide as an adjunct to insulin therapy appears to be safe and efficacious in improving long-term overall glycemic and weight control in patients with type 2 diabetes. Importantly, the improvement in glycemic control with pramlintide was accompanied by a mean reduction in body weight and no overall increase in severe hypoglycemia. Because of these unique and desirable clinical benefits, pramlintide may become a valuable addition to the arsenal of therapies available to patients with type 2 diabetes.
Well I lost the other link, but you get the pricture.
Barb's earned her piece of bday cake!!!!!
